Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

NCT ID: NCT02345330


Title
A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck
Purpose
This study will assess the safety and effectiveness of intratumoral plasmid interleukin-12 DNA injection (pIL-12) with electroporation (EP) in treatment-refractory metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). Intratumoral pIL-12 EP is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.
Details
Conditions
Head and Neck Squamous Cell Carcinoma
Keywords
Source
OncoSec Medical Incorporated
Sponsors
OncoSec Medical Incorporated
Status
Completed
Acronym
Last Updated
11 Dec 2016
URL
Official Link
Locations
United States